All Updates

All Updates

icon
Filter
Partnerships
BenevolentAI identifies new target for AstraZeneca
AI Drug Discovery
May 17, 2022
This week:
Funding
MeliBio receives strategic investment from Future Food Fund
Alternative Ingredients
Yesterday
Product updates
Catchfree launches microalgae-based shrimp alternative
Plant-based Meat
Yesterday
Product updates
AQUA Cultured Foods introduces fermentation-based raw tuna alternative
Plant-based Meat
Yesterday
Management news
SDI Element Logic rebrands as Element Logic
Logistics Tech
Yesterday
Geographic expansion
Wayve opens office and commences testing of automated driving features in US
Auto Tech
Yesterday
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

May 17, 2022

BenevolentAI identifies new target for AstraZeneca

Partnerships

  • Pharma giant AstraZeneca has added another new target for idiopathic pulmonary fibrosis (IPF) to its drug portfolio, which was identified by London-based AI drug discovery company BenevolentAI by leveraging its AI-powered target discovery platform. BenevolentAI will receive a milestone payment as part of the agreement.

<ul><li>The novel target is the third one to enter the pharma giant’s drug portfolio through the collaboration initiated by the two parties in April 2019 to identify potential targets for IPF and chronic kidney disease (CKD). The duo also extended the partnership’s focus to two additional disease areas—systemic lupus erythematosus and heart failure—in January 2022.</ul>

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.